New Biktarvy® data presented at IAS 2023 further demonstrate safety and efficacy profile in a broad range of people and communities affected by the global HIV epidemic
Biktarvy evaluated in a diverse range of people with HIV, including pregnant women and pediatric populations
96-week data from ALLIANCE trial show durability of Biktarvy in adults with HIV and HBV coinfection
Read the full press release here.
Source : Gilead Sciences, Inc.
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.